Erdanat 3 mg Erdanat 3 mg contains erdafitinib, a targeted medicine used to treat certain forms of advanced bladder and urinary tract cancer. It is intended for patients whose cancer has specific changes in the FGFR (Fibroblast Growth Factor Receptor) genes. The medicine works by blocking signals that encourage cancer cells to grow and multiply, helping to slow the progression of the disease.

Effects & Benefits Helps slow the growth of cancer cells with FGFR gene mutations. Supports the treatment of advanced or metastatic urothelial cancer. Targets cancer cells more precisely than many traditional cancer treatments.